tetano
Editor, Senior Moderator
[h=1]Efficacy of recombinant measles virus expressing highly pathogenic avian influenza virus (HPAIV) antigen against HPAIV infection in monkeys[/h]
Received: 27 January 2017 Accepted: 07 July 2017 Published online: 20 September 2017
[h=2]Abstract[/h] Highly pathogenic avian influenza virus (HPAIV) is a serious threat not only to domestic fowls but also to humans. Vaccines inducing long-lasting immunity against HPAIV are required. In the present study, we generated recombinant measles virus (MV) expressing the hemagglutinin protein of HPAIV without the multibasic site necessary for its pathogenicity in chickens using the backbone of an MV vaccine strain (rMV-Ed-H5HA) or a wild-type MV-derived mutant (rMV-HL-Vko-H5HA). We examined protective efficacy of the candidate vaccines in the monkey infection model by the challenge with a HPAIV (H5N1). Cynomolgus monkeys inoculated with the candidate vaccines produced both anti-H5 HA and anti-MV antibodies. They recovered earlier from influenza symptoms than unvaccinated monkeys after the challenge with the HPAIV strain. Chest radiography and histopathological analyses confirmed less severe pneumonia in the vaccinated monkeys. Vaccination tended to suppress viral shedding and reduced the interleukin-6 levels in the lungs. Furthermore, the vaccination with rMV-Ed-H5HA of monkeys with pre-existing anti-MV immunity induced the production of anti-H5 HA antibodies. These results suggest that both candidate vaccines effectively reduce disease severity in na?ve hosts, and that rMV-Ed-H5HA is a particularly good candidate vaccine against HPAIV infection.
full article
https://www.nature.com/articles/s41598-017-08326-x?WT.feed_name=subjects_immunology
- Tomoko Fujiyuki,
- Ryo Horie,
- Misako Yoneda,
- Takeshi Kuraishi,
- Fumihiko Yasui,
- Hyun-jeong Kwon,
- Keisuke Munekata,
- Fusako Ikeda,
- Miho Hoshi,
- Yuri Kiso,
- Mio Omi,
- Hiroki Sato,
- Hiroshi Kida,
- Shosaku Hattori,
- Michinori Kohara &
- Chieko Kai
- Scientific Reports 7, Article number: 12017 (2017)
- doi:10.1038/s41598-017-08326-x
- Download Citation
Received: 27 January 2017 Accepted: 07 July 2017 Published online: 20 September 2017
[h=2]Abstract[/h] Highly pathogenic avian influenza virus (HPAIV) is a serious threat not only to domestic fowls but also to humans. Vaccines inducing long-lasting immunity against HPAIV are required. In the present study, we generated recombinant measles virus (MV) expressing the hemagglutinin protein of HPAIV without the multibasic site necessary for its pathogenicity in chickens using the backbone of an MV vaccine strain (rMV-Ed-H5HA) or a wild-type MV-derived mutant (rMV-HL-Vko-H5HA). We examined protective efficacy of the candidate vaccines in the monkey infection model by the challenge with a HPAIV (H5N1). Cynomolgus monkeys inoculated with the candidate vaccines produced both anti-H5 HA and anti-MV antibodies. They recovered earlier from influenza symptoms than unvaccinated monkeys after the challenge with the HPAIV strain. Chest radiography and histopathological analyses confirmed less severe pneumonia in the vaccinated monkeys. Vaccination tended to suppress viral shedding and reduced the interleukin-6 levels in the lungs. Furthermore, the vaccination with rMV-Ed-H5HA of monkeys with pre-existing anti-MV immunity induced the production of anti-H5 HA antibodies. These results suggest that both candidate vaccines effectively reduce disease severity in na?ve hosts, and that rMV-Ed-H5HA is a particularly good candidate vaccine against HPAIV infection.
full article
https://www.nature.com/articles/s41598-017-08326-x?WT.feed_name=subjects_immunology